First-ever CRISPR gene-editing drug, made by 2 Boston companies, approved in US

In a first for the Nobel Prize-winning gene-editing technology, a CRISPR-based drug has been approved in the U.S.

The Food and Drug Administration gave the green light Friday to exa-cel, a drug made by two Boston-based companies, Vertex Pharmaceuticals Inc. and CRISPR Therapeutics Inc. It will be marketed under the name Casgevy.

STAY IN THE KNOW

	Watch NBC10 Boston news for free, 24/7, wherever you are.
	Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters.

More on this story from Boston Business Journal